Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term docetaxel. Found 13 abstracts

Patel NR, Piroyan A, Ganta S, Morse AB, Candiloro KM, Solon AL, Nack AH, Galati CA, Bora C, Maglaty MA, O'Brien SW, Litwin S, Davis B, Connolly DC, Coleman TP. In Vitro and In Vivo evaluation of a novel folate-targeted theranostic nanoemulsion of docetaxel for imaging and improved anticancer activity against ovarian cancers. Cancer Biol Ther. 2018 Jul 03;19(7):554-64.   PMCID: PMC5989790
Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Jul;123(13):2489-96.   PMCID: PMC5474197
Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Mar 21;.
Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, Hudes GR. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer. 2012 Jan;48(1):85-93.   PMCID: Private funding
Mackay HJ, Buckanovich RJ, Hirte H, Correa R, Hoskins P, Biagi J, Martin LP, Fleming GF, Morgan R, Wang L, Polintan R, Oza AM. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecologic Oncology. 2012 Apr;125(1):136-40.   PMCID: pmc3303987
Makhov P, Golovine K, Canter D, Kutikov A, Simhan J, Corlew MM, Uzzo RG, Kolenko VM. Co-administration of piperine and docetaxel results in improved anti-tumor efficacy via inhibition of CYP3A4 activity. The Prostate. 2012 May;72(6):661-7.   PMCID: PMC3208085
Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR. Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Annals of Oncology. 2012 May;23(5):1234-40.   PMCID: not NIH funded
Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu ZH, Watson JC, Weiner LM, Cohen SJ. Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology-Cancer Clinical Trials. 2011 Feb;34(1):70-5.   PMCID: PMC3030655
Makhov P, Kutikov A, Golovine K, Uzzo RG, Canter DJ, Kolenko VM. Docetaxel-Mediated Apoptosis in Myeloid Progenitor TF-I Cells Is Mitigated by Zinc: Potential Implication for Prostate Cancer Therapy. The Prostate. 2011 Sep;71(13):1413-9.   PMCID: PMC3106130
Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research. 2010 Apr;16(8):2450-7.   PMCID: not NIH funded
Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Annals of Oncology. 2009 Jul;20(7):1242-8.   PMCID: PMC2699385
Beer TM, Higano CS, Saleh M, Dreicer R, Hudes G, Picus J, Rarick M, Fehrenbacher L, Hannah AL. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Investigational New Drugs. 2007 Dec;25(6):565-70.
Swaby RF, Bhalla KN. Importance of rational pre-clinical development - Gemcitabine comes of age. CANCER BIOLOGY & THERAPY. 2005 Aug;4(8):872-3.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term docetaxel

docetaxel chemotherapy therapy clinical-trials paclitaxel prostate androgen deprivation cancer apoptosis high risk radiation postprostatectomy angiogenesis ketoconazole Aflibercept (VEGF Neoplasm Staging trial system therapeutic use BMS-247550 nanoemulsions GROWTH-FACTOR Neoplasm Grading folic acid mice Prostatic neoplasms recommendations ixabepilone Proportional Hazards Models soft-tissue sarcomas Taxoids uterus folate receptor-alpha Prostatectomy tissues Safety breast cancer Anilides Prostatic Neoplasms erlotinib cells growth-factor vitro Siltuximab docetaxel chemotherapy-prostate cancer-second-line-trabectedin working group in-vitro Intensity-Modulated Radiotherapy mutations gemcitabine Trap) Prednisone Mitoxantrone DESOXYEPOTHILONE-B piperine methods survival interleukin-6 PLUS CISPLATIN Adenocarcinoma breast-cancer Male tumors ADVANCED SOLID TUMORS ADVANCED ESOPHAGOGASTRIC CANCER Phase II HUMAN TUMOR XENOGRAFTS irinotecan GASTROESOPHAGEAL ADENOCARCINOMA Carcinosarcoma target esophageal cancer uptake agonists randomized-trial plus gemcitabine Antineoplastic Agents gemcitabine plus mixed mullerian tumors checkpoint-deficient bevacizumab CHEMOTHERAPY colorectal-cancer circulating endothelial-cells drug-interactions ifosfamide Androgen Antagonists mesna CLINICAL-TRIALS randomized-trials zinc Gonadotropin-Releasing Hormone nude-mice lung-cancer Interleukin-6 pancreatic adenocarcinoma cell cycle arrest metabolism plasma-levels ADVANCED GASTRIC-CANCER cycle arrest Kallikreins carboplatin Nitriles Oncology oncology-group et-743 d-dimer DNA TOPOISOMERASE-I second line chemotherapy Treatment efficacy abiraterone acetate transporter Adult factor-kappa-b metastatic breast-cancer inhibition pathway end-points endothelial growth-factor Middle Aged Ovarian cancer blood Uterine leiomyosarcoma Multivariate Analysis ADJUVANT CHEMOTHERAPY coagulation prostate cancer Tosyl Compounds glycoprotein RANDOMIZED-TRIAL 2-STAGE DESIGNS theranostic Adjuvant Chemoradiotherapy phase-ii trial Conformal Radiotherapy pathology pharmacokinetics RECEPTOR Disease-Free Survival braf gene 2010 bono js-35 ann c eur soc med Prostate-Specific Antigen agents MITOXANTRONE PLUS PREDNISONE Aged citrate metabolism prednisone CNTO 328 monoclonal antibody
Last updated on Wednesday, February 05, 2020